The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from CNW Group

Research, Education and Commercial Partnership with Dr. Bruce Ames and Juvenon, Inc.

Thursday, February 09, 2012

Research, Education and Commercial Partnership with Dr. Bruce Ames and Juvenon, Inc.10:43 EST Thursday, February 09, 2012Exclusive Rights to Patents to Develop and Commercialize Healthcare Practitioner Dietary Supplements in North AmericaQUEBEC CITY, Feb. 9, 2012 /CNW Telbec/ - Atrium Innovations Inc. (TSX: ATB), a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals, today announces a multi-year research, education and commercial partnership with Juvenon, Inc. and its founder Dr. Bruce Ames, a world renowned scientist. The agreement provides Atrium with rights to patents for the development and commercialization of products promoting healthy aging.  The rights are exclusive to Atrium for healthcare practitioners in North America, and also include general distribution and endorsement rights in Europe.The patents licensed are based on a discovery by Dr. Ames and a team of scientists at the University of California, Berkeley, demonstrating that the cellular aging process could be slowed with the combination of acetyl L-carnitine, a natural energy-boosting nutrient, and alpha lipoic acid, a powerful anti-oxidant."As we age, specific nutrients become essential for the long-term maintenance of health," explained Dr. Ames.  "These concepts are complex. Atrium is the best partner for a research and product development collaboration and for accessing healthcare professionals with a fundamental understanding of the role of targeted nutrition therapy.""We are pleased to both support this cutting-edge research and secure the rights to develop science-based, innovative products in a growing market," said Barry W. Ritz, Ph.D, Atrium's Vice President, Scientific and Regulatory Affairs. "The first two products - RejuvenAge and RejuvenAge Ultra - have been launched by Pure Encapsulations. Other Atrium brands are also expected to release products in 2012.""Our capacity to leverage the patents, through the participation of several of our brands, was key to our ability and decision to obtain the rights from Juvenon. This agreement highlights the value of Atrium's critical mass to create synergies, as well as our ongoing commitment to science and innovation," concluded Dr. Ritz.About AtriumAtrium Innovations Inc. is a globally recognized leader in the development, manufacturing, and commercialization of innovative, science-based dietary supplements endorsed by health professionals. The Company distributes its extensive portfolio of products mainly in the healthcare practitioner and health food and specialized store channels, with a primary focus in North America and Europe. Atrium is at the forefront of science, innovation and education in the dietary supplement industry.  The Company has over 1,100 employees and operates eight manufacturing facilities. Additional information is available at www.atrium-innovations.com.About Dr. Bruce Ames, Ph.D and JuvenonInc.Dr. Ames is the founder of JuvenonInc. which has a mission to develop and market nutritional health supplements that help maintain vigor and functionality as we age. Most famous for developing the "Ames Test", Dr. Ames is currently a Professor Emeritus of Biochemistry and Molecular Biology at the University of California, Berkeley, Senior Scientist at Children's Hospital Oakland Research Institute and a member of the National Academies of Science.  He has authored over 500 scientific publications during his career, making him one of the most cited scientists in any field.  Dr. Ames' current research focuses on cellular aging and the identification of nutrients associated with longevity.  For more information on this research, visit www.juvenon.com.For further information: Investor Relations:  Mario Paradis Vice President and Chief Financial Officer  Tel.: 418 652-1116  mp@atrium-innovations.com Pierre Boucher MaisonBrison Communications Tel.: 514 731-0000, ext. 237 pierre@maisonbrison.comMedia Relations: Amélie Germain  Director of Communications Tel.: 418 652-1116 ag@atrium-innovations.com